Genomic polymorphisms of drug metabolisms associated with overall survival (OS) in advanced non-small cell lung cancer (NSCLC) treated with gemcitabine (GEM) or taxanes.

被引：0
|
作者：
Zhang, L. [1 ]
Zhou, C. [1 ]
机构：
[1] Tongji Univ, Shanghai Pulm Hosp, Shanghai 200092, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.7627
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7627
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Gemcitabine and cisplatin in advanced non small cell lung cancer (NSCLC)
    Garcia-Gomez, R
    Lopez-Criado, P
    Guevara, S
    Lahoz, C
    Chaib, C
    Gonzalez, C
    Santiago, J
    De Alvaro, J
    Carrion, R
    Perez-Manga, G
    ANNALS OF ONCOLOGY, 1998, 9 : 93 - 94
  • [32] Joint model of longitudinal tumor size and overall survival (OS) in non-small cell lung cancer (NSCLC): A Bayesian approach
    Al-Huniti, Nidal
    Xu, Hongmei
    Zhou, Diansong
    Edlund, Helena
    Aksenov, Sergey
    Helmlinger, Gabriel
    Dunyak, James
    CANCER RESEARCH, 2018, 78 (13)
  • [33] Bayesian formulation of a joint model of longitudinal tumor size and overall survival (OS) in Non-Small Cell Lung Cancer (NSCLC)
    Al-Huniti, Nidal
    Dunyak, James
    Aksenov, Sergey
    Zhou, Diansong
    Xu, Hongmei
    Masson, Eric
    Helmlinger, Gabriel
    Edlund, Helena
    Stanski, Donald
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 : S141 - S141
  • [34] Overall survival (OS) of selected patients (Pts) with non-small cell lung cancer (NSCLC) receiving nivolumab beyond progression
    Genova, C.
    Rijavec, E.
    Rossi, G.
    Biello, F.
    Barletta, G.
    Tagliamento, M.
    Grossi, F.
    ANNALS OF ONCOLOGY, 2017, 28
  • [35] Overall Survival (OS) of Pathological N2 Non-Small Cell Lung Cancer (NSCLC) After Surgical Resection
    Bourdages-Pageau, E.
    Vieira, A.
    Labbe, C.
    Figueroa, P. Ugalde
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2233 - S2233
  • [36] Vinorelbine/gemcitabine in advanced non-small cell lung cancer (NSCLC):: a phase I trial
    Krajnik, G
    Wein, W
    Greil, R
    Marhold, F
    Mohn-Staudner, A
    Kummer, F
    Malayeri, R
    Zöchbauer-Müller, S
    Huber, H
    Pirker, R
    EUROPEAN JOURNAL OF CANCER, 1998, 34 (12) : 1977 - 1980
  • [37] Weekly administration of gemcitabine plus docetaxel in advanced non-small cell lung cancer (NSCLC).
    Sun, Y
    Li, J
    Wu, Y
    Li, L
    Gu, L
    Zhang, L
    Wang, J
    Zhang, X
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 698S - 698S
  • [38] A pilot-study with gemcitabine (GEM), vinorelbine (VNR) and cisplatin (P) in the treatment of advanced non-small cell lung cancer (NSCLC).
    Laack, E
    Mende, T
    Dürk, H
    Kneba, M
    Dickgreber, N
    Müller, T
    Scholtze, J
    Graeven, U
    Hirth, M
    Hossfeld, DK
    ANNALS OF ONCOLOGY, 2000, 11 : 115 - 115
  • [39] Phase II study of paclitaxel and gemcitabine in advanced non-small cell lung cancer (NSCLC).
    Lazaro, M
    Jorge, M
    Castellanos, J
    ANNALS OF ONCOLOGY, 2000, 11 : 109 - 109
  • [40] Sarcopenia Is Associated With Worse Overall Survival in Patients With Locally Advanced Non-Small Cell Lung Cancer
    Grendarova, P.
    Arora, R.
    Bebb, G. D.
    D'Silva, A.
    Banerjee, R. N.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : S201 - S202
12345